Volvo's New Seat Belts Will Adapt to Your Body
As a country, the National Highway Traffic Safety Administration says we're doing a pretty good job at wearing our seat belts — the national use rate was 91.2% in 2024. And it probably helps that the NHTSA has widely publicized its Click It or Ticket campaign encouraging drivers and passengers to buckle up. However, seat belts are not always ideal for every body size and shape, and they aren't always a great fit.
The lap belt and shoulder belt are supposed to be taut against the pelvis and diagonally across the rib cage to protect internal organs; a good fit is highly dependent on height, weight and seat position. Volvo now has an answer to that issue with a new multi-adaptive safety belt that not only adjusts to each passenger's body type but to traffic variations as well.
Volvo — the company that perfected the modern three-point safety belt way back in 1959 — will include these new seat belts on the upcoming all-electric EX60. The Superset technological building blocks that underpin the EX60 are what allow this safety belt tech to work.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Why One Analyst Thinks Tesla Could Dominate the 'Low-Altitude Economy'
"Look up, your ride has arrived," is a message some see as eventually landing in your inbox. 'In our view, the low altitude economy (LAE) may eventually vastly exceed the size of today's automotive market,' wrote Morgan Stanley analyst Adam Jonas in a research note earlier this week. That term refers to aerial commercial activities conducted within one mile of the earth's surface, airspace now sparsely occupied by helicopters and small drones. Analysts expect advancements in artificial intelligence and robotics to support the launch of new aircraft—notably, electric vertical take-off and landing (eVTOL) vehicles—with applications in areas like logistics/distribution, public security and emergency services, tourism, urban commuting, and intercity transportation. Morgan Stanley forecasts the total addressable 'Urban Air Mobility' (UAM) market will be valued at $1 trillion by 2040 and $9 trillion by 2050. Not everybody's expectations are quite that high: Bank of America recently estimated a market worth $23 billion by 2035. BofA expects adoption to remain relatively slow until at least that year, when it anticipates economies of scale and battery technologies to improve eVTOL cost and accessibility. Whatever the size of the pie, the companies vying for a slice of it include upstarts like Archer Aviation (ACHR), which is currently testing an eVTOL model and partnering with defense contractor Anduril to develop military applications, and Joby Aviation (JOBY), which is in the process of getting its air taxi certified for passenger rides. Morgan Stanley's Jonas thinks those companies could face formidable competition from Tesla (TSLA). The EV maker hasn't announced any intention to develop eVTOLs, but CEO Elon Musk has discussed the need for a homegrown low-altitude economy in the U.S. When Jonas, on Tesla's most recent earnings call, asked Musk for his thoughts on the U.S. and China's AI and robotics rivalry, Musk expressed concern about America's limited drone manufacturing capabilities. 'Any country that cannot manufacture its own drones is doomed to be the vassal state of any country that can,' he said, quoting X user "@naval." 'And we can't. America cannot currently manufacture its own drones.' Tesla, Jonas says, 'has a host of relevant skills to be a factor' in the commercial and military LAE, including its work in manufacturing, autonomy, electric motors and batteries, and robotics. Jonas estimates Tesla's share of a future $9 trillion UAM market could add between $100 and $1,000 to its share price. Tesla's work on autonomous vehicles could give it a leg up on LAE competitors. "Any advancement in the science of autonomous cars accelerates the advancement of autonomous aerial drones," Jonas wrote. Tesla is expected to launch its first robotaxi operation in Austin, Texas, later this month. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22 minutes ago
- Yahoo
Analysts Look to Tesla's Robotaxi Launch After Stock Hit From Musk-Trump Spat
Tesla is expected to launch its autonomous ride hailing service later this month, perhaps as soon as this week. The company has yet to confirm or deny a report from Bloomberg that it is targeting a June 12 launch for the robotaxi. The EV maker's stock could use a lift after a week marked by a spat between CEO Elon Musk and President (TSLA) is expected to launch its robotaxi service in Austin, Texas, as soon as this week, with the electric vehicle maker's stock in need of a lift after a week marked by political strife between CEO Elon Musk and President Trump. The stock rebounded nearly 4% to close just above $295 Friday, after tumbling 14% on Thursday. They've lost roughly one-quarter of their value since the start of the year. Tesla bulls believe a robotaxi program could drive substantial upside in the company's stock. Bloomberg last month reported that Tesla was targeting a June 12 launch, citing a person familiar with the matter, adding that the date could change. The company has not confirmed that date, and Tesla did not respond to Investopedia's request for comment in time for publication. Musk said in last month's earnings call and a May 20 interview with CNBC that the company was still on track to launch the program by the end of the month. The start of the program, Musk told CNBC, will likely be about 10 Model Y vehicles operating autonomously, with the company later expanding to more vehicles and cities. Tesla owners will eventually be able to add their vehicle to the available fleet of Teslas to rent for a ride, Musk has said, which could help Tesla scale the project before the Cybercab goes into production next year. Oppenheimer analysts recently wrote that the company's ability to get its software to drive fully autonomously with its current suite of cameras could be "key to its technology leadership and stock performance," but added they believe it might take at least one or two more hardware and software updates before Tesla can deliver reliable autonomous performance. More bullish analysts, like Wedbush's Dan Ives, have said they think successful autonomous driving software will be the start of technology that will eventually add $1 trillion in value to the company. Overall, analysts are somewhat divided on Tesla's stock, with 10 of the brokers tracked by Visible Alpha giving the stock a "buy" rating, with four "hold" and four "sell" ratings. Their average price target is about $304, slightly above Friday's closing level, but their price targets range from as low as $120 to as high as $500. Read the original article on Investopedia
Fox News
37 minutes ago
- Fox News
Psychedelics as potential mental health treatment are explored by Trump administration
The Trump administration has expressed interest in exploring psychedelics for their potential in treating PTSD and other debilitating mental health issues, various officials have shared. "The Department shares the goal of ensuring that all Americans — especially our nation's veterans — have access to safe and effective treatments for conditions such as PTSD, addiction and depression," a spokesperson for the U.S. Department of Health and Human Services (HHS), run by Sec. Robert J. Kennedy Jr., said in a statement provided to Fox News Digital. "Secretary Kennedy is committed to applying rigorous, evidence-based science to research efforts aimed at addressing these serious health challenges." In recent years, researchers have been actively investigating the potential of psychedelics, such as MDMA and psilocybin ("magic mushrooms") to treat mental health disorders. MDMA is not approved for clinical use by the U.S. Food and Drug Administration (FDA), but can be studied in clinical settings. Psilocybin is listed as a Schedule I substance under the Controlled Substances Act, which means it has "a high potential for abuse, [is not] currently accepted for medical use in treatment in the United States, and [has] a lack of accepted safety for use under medical supervision." Psilocybin-assisted therapy, however, is legal in Oregon, Colorado and New Mexico. Psychedelic medicines are "showing real promise," according to Dr. Luke Twelves, general practitioner and vice president of medical for Lindus Health in London. Clinical trials have found such treatments safe and effective for patients battling serious mental health issues, according to Twelves. "Take psilocybin, for example — it's demonstrating remarkable results for severe depression that hasn't responded to other medications," he told Fox News Digital. "MDMA is showing similar breakthroughs for PTSD treatment." Clinical trials are also investigating how psychedelics could help with end-of-life anxiety, addiction, eating disorders, chronic pain and OCD, he added. Researchers have faced challenges in terms of regulatory hurdles and proper placebo controls, Twelves said. "Given that these treatments could transform [the] lives of people suffering from conditions where nothing else has worked effectively, it's crucial that we complete this research properly," he said. "The goal is to bring safe, proven psychedelic therapies to the patients who need them most." At President Trump's May 1 cabinet meeting, Department of Veterans Affairs Secretary Doug Collins said that "we're opening up the possibility of psychedelic treatment." Retired Army Sergeant Jonathan Lubecki recently told Fox News' Alexandria Hoff that MDMA stopped his PTSD while he was participating in a clinical trial. "[I] took my first dose of MDMA. I've only taken it three times as part of the clinical trial, haven't taken it since, and haven't found the need to take it since, because I haven't had PTSD," he said. Peter Kasperowicz, Department of Veterans Affairs press secretary, told Fox News Digital the department is safely exploring all avenues that promote the health of veterans. "Preliminary findings have produced positive results on psychedelic-assisted therapies for treating mental health conditions," he said. The VA is currently running 11 clinical trials in various phases, with a total of some 800 veterans expected to participate. "The goal of these trials is to determine whether compounds such as MDMA and psilocybin can treat veterans with post-traumatic stress disorder, treatment-resistant depressive disorder, major depressive disorder and potentially other mental health conditions," said Kasperowicz. An MDMA study published in the Jan. 2025 issue of The American Journal of Psychiatry found that the substance is "unlike classical psychedelics." The study noted, "MDMA allows the individual to maintain intact ego functioning and a greater degree of cognitive and perceptual lucidity while still experiencing a prosocial altered state of consciousness that facilitates deeply emotional therapeutic breakthroughs." The researchers concluded that MDMA showed "enhanced levels of trust, empathy, self-compassion and a 'window of tolerance'" that traditional psychotherapy lacks. Doug Drysdale, CEO of the Canadian pharmaceutical company Cybin, told Fox News Digital that "the time is now to address the mental health crisis." He said it is "gratifying" that administration officials value the potential benefits of looking into alternative mental health treatments. "The time is now to address the mental health crisis." Cybin is currently in phase 3 of a study of CYB003, a type of psilocybin that has been granted breakthrough therapy designation by the FDA as an additional treatment for major depressive disorder (MDD). "In Cybin's completed Phase 2 MDD study, long-term efficacy results showed that 71% of participants were in remission from depression, and 100% of participants responded to treatment at 12 months after just two 16 mg doses of CYB003," said Drysdale. Dr. Marc Siegel, clinical professor of medicine at NYU Langone Medical Center and Fox News' senior medical analyst, previously interviewed two of the country's top researchers on psychedelics — Dr. Rachel Yehuda, founder and director of the Center for Psychedelic Psychotherapy and Trauma Research at Mt. Sinai in New York, and Dr. Charles Marmar, director of the PTSD research program at NYU Langone. "There is a huge downside in terms of unregulated recreational uses." "They agree there is therapeutic potential if very carefully studied under very strict medical guidance, but there is a huge downside in terms of unregulated recreational uses," Siegel told Fox News Digital at the time. "Both doctors see likely therapeutic value to psychedelics if carefully managed by medical experts," Siegel added. Ryan Moss, chief science officer at Filament Health, a clinical-stage natural psychedelic drug development company in Canada, emphasized it's important to administer psychedelics in a safe setting when treating mental health conditions. For more Health articles, visit "Psychedelic experiences can sometimes feature anxiety, hallucinations and paranoia," Moss previously told Fox News Digital. "Some patients using traditional psychedelics have reported experiencing adverse cardiovascular events during clinical trials." To mitigate these risks, Moss recommended clinical trial participants receive thorough preparation and monitoring by trained professionals during sessions. Melissa Rudy and Angelica Stabile, both of Fox News Digital, contributed reporting.
